Status:
UNKNOWN
The Role of Optic Nerve Sheath Fenestration in Leukemic Patients Having Increased Intracranial Pressure
Lead Sponsor:
Alexandria University
Conditions:
Leukemic Patients With Increased Intracranial Pressure
Optic Nerve Sheath Fenestration
Eligibility:
All Genders
6-18 years
Phase:
PHASE2
PHASE3
Brief Summary
Optic nerve sheath fenestration (ONSF) first described by De Wecker in 1872 for the treatment of neuroretinitis. Since then, optic nerve sheath fenestration has become well established procedure for t...
Detailed Description
Optic nerve sheath fenestration (ONSF) first described by De Wecker in 1872 for the treatment of neuroretinitis. Since then optic nerve sheath fenestration has become well established procedure for tr...
Eligibility Criteria
Inclusion
- Evidence of progressive visual loss and papilledema did not improve despite the maximal medical therapy prescribed.
- Informed written consent was obtained from the parents/care providers of the study participants.
Exclusion
- Can not get the informed consent
Key Trial Info
Start Date :
June 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04431882
Start Date
June 1 2019
End Date
June 30 2020
Last Update
June 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alexandria Faculty of Medicine
Alexandria, Egypt